See this article Novel Agents In CML Therapy: Tyrosine Kinase Inhibitors and Beyond
See also these links:
Novel Agents In CML Therapy: Tyrosine Kinase Inhibitors and Beyond
Started by
cousineg
, Nov 25 2012 09:58 PM
8 replies to this topic
#2
alexamay09
-
- Members
-
- 50 posts
Advanced Member
Posted 27 November 2012 - 06:32 AM
Great article, thanks.
alex
#3
Tedsey
-
- Members
-
- 85 posts
Advanced Member
Posted 29 November 2012 - 04:24 AM
Thank you. This is a very hopeful article. May we all live long enough in the chronic stage to benefit from some of these suggested therapies. May these advances happen in what is reasonably soon for us (i.e. not like a breakthrough in 10-20 years, which in the research world is considered quick). Presently, our only hope for survival, if our disease progresses today, is a successful SCT. And if successful, a hope that GVH or other complications therefrom does not snuff us out faster than what the CML would have.
Long life, or, at least, an average lifespan to all of us,
Tedsey
#4
Trey
-
- PS Beta Group
-
- 1,705 posts
Advanced Member
- LocationSan Antonio, Texas
Posted 29 November 2012 - 09:36 AM
Tedsey's new slogan:
"LIVE AVERAGE!"
We should make T-shirts.
#5
PhilB
-
- Members
-
- 130 posts
Advanced Member
Posted 29 November 2012 - 10:51 AM
Trey wrote:
"LIVE AVERAGE!"
We should make T-shirts.
Only if we can have a picture of Don Bradman on the front - test batting average 99.94. Come on guys, lets show some ambition here!
#6
CallMeLucky
-
- Members
-
- 216 posts
Advanced Member
- LocationCT
Posted 29 November 2012 - 12:30 PM
Date - Lab - Scale - Drug - Dosage MG - PCR
2010/Jul - MSKCC - Non-IS - Gleevec - 400 - 1.2%
2010/Oct - MSKCC - Non-IS - Gleevec - 400 - 0.25%
2010/Dec - MSKCC - Non-IS - Gleevec - 400 - 0.367%
2011/Mar - MSKCC - Non-IS - Gleevec - 400 - 0.0081%
2011/Jun - MSKCC - Non-IS - Gleevec - 400 - 0%
2011/Sep - MSKCC - Non-IS - Gleevec - 400 - 0.00084%
2011/Dec - MSKCC - Non-IS - Gleevec - 400 - 0%
2012/Mar - MSKCC - Non-IS - Gleevec - 400 - 0.004%
2012/Jun - MSKCC - Non-IS - Gleevec - 400 - 0%
2012/Sep - MSKCC - Non-IS - Gleevec - 400 - 0%
2012/Dec - MSKCC - Non-IS - Sprycel - 100 - 0%
2013/Jan - Quest - IS - Sprycel - 50-60-70 - 0%
2013/Mar - Quest - IS - Sprycel - 60-70 - 0%
2013/Apr - CUMC - Non-IS - Sprycel - 50 - 0.036%
2013/May - CUMC - Non-IS - Sprycel - 50 - 0.046%
2013/Jun - Genoptix - IS - Sprycel - 50 - 0.0239%
2013/Jul - Genoptix - IS - Sprycel - 70 - 0.0192%
2013/Jul - Genoptix - IS - Sprycel - 70 - 0.0034%
2013/Oct - Genoptix - IS - Sprycel - 70 - 0.0054%
2014/Jan - Genoptix - IS - Sprycel - 70 - 0.0093%
2014/Mar - Genoptix - IS - Sprycel - 100 - 0.013%
2014/Apr - Genoptix - IS - Sprycel - 100 - 0.0048%
2014/Jul - Genoptix - IS - Sprycel - 100 - 0%
2014/Nov - Genoptix - IS - Sprycel - 100 - 0.047%
2014/Dec - Genoptix - IS - Sprycel - 100 - 0%
2015/Mar - Genoptix - IS - Sprycel - 100 - 0%
2015/Jun - Genoptix - IS - Sprycel - 100 - 0%
2015/Sep - Genoptix - IS - Sprycel - 100 - 0%
2015/Dec - Genoptix - IS - Sprycel - 100 - 0%
2016/Mar - Genoptix - IS - Sprycel - 100 - 0.0228%
2016/Jun - Genoptix - IS - Sprycel - 100 - 0%
2016/Sep - Genoptix - IS - Sprycel - 100 - 0%
2016/Dec - Genoptix - IS - Sprycel - 100 - 0%
2017/Mar - Genoptix - IS - Sprycel - 100 - 0%
2017/Jun - Genoptix - IS - Sprycel - 100 - 0%
2017/Sep - Genoptix - IS - Sprycel - 100 - 0%
2017/Dec - Genoptix - IS - Sprycel - 100 - 0%
#7
TeddyB
-
- Members
-
- 203 posts
Advanced Member
Posted 29 November 2012 - 02:33 PM
Live long and prosper. (For those who get it)
#9
Trey
-
- PS Beta Group
-
- 1,705 posts
Advanced Member
- LocationSan Antonio, Texas
Posted 29 November 2012 - 11:01 PM
A duck and a Brit walk into a bar. The Brit should have ducked. Speaking of ducks, the record for the most ducks in Test cricket is 43. Speaking of which, those who don't "get it" as Phil suggests may also be declared to be "out for naught".
So maybe our T-Shirt says "LIVE AVERAGE AND DO O.K." on the front and on the back it says "Stay Back 30 Feet -- TKI at Work".
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users
